Canonic aims to develop and bring to market medical-grade cannabis using a genomic approach. The company will initially focus on creating improved cannabis varieties, focusing on yield, stability, and specific metabolite composition.
The company is a subsidiary of Evogene. Canonics development efforts will be based on the utilization of Evogenes computational predictive biology platform, which has already demonstrated success in addressing similar objectives for other crops.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Canonic Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Oct 19, 2021
www.prnewswire.com
Canonic Announces Full Commercial Launch of its First Medical Cannabis Products in Israel
#Customers
Aug 31, 2021
www.prnewswire.com
Canonic Announces Pre-Launch of its First Generation Medical Cannabis Products in Israel
#Customers
Feb 24, 2021
www.prnewswire.com
Cannbit, subsidiary of Tikun Olam-Cannbit, and Canonic of Evogene group announce collaboration for the development of novel medical cannabis products
#Partners
Dec 23, 2020
www.prnewswire.com
Canonic Announces Signing of First Cultivation Agreement for its Medical Cannabis Varieties
#Partners #Customers
Nov 11, 2020
www.prnewswire.com
Canonic Received Approval for Propagation of Medical Cannabis from the Israel Medical Cannabis Agency